R
Roger B. Cohen
Researcher at Fox Chase Cancer Center
Publications - 110
Citations - 13043
Roger B. Cohen is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Internal medicine & Cancer. The author has an hindex of 34, co-authored 83 publications receiving 12136 citations. Previous affiliations of Roger B. Cohen include University of Chicago & University of Virginia Health System.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
James A. Bonner,Paul M. Harari,Jordi Giralt,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,José Baselga,Sharon A. Spencer,Junming Zhu,Hagop Youssoufian,Eric K. Rowinsky,K. Kian Ang +12 more
TL;DR: Overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients.
Journal ArticleDOI
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Marshall R. Posner,Diane Hershock,Cesar R. Blajman,Elizabeth Mickiewicz,Eric Winquist,Vera Gorbounova,Sergei Tjulandin,Dong M. Shin,Kevin J. Cullen,Thomas J. Ervin,Barbara A. Murphy,Luis E. Raez,Roger B. Cohen,Monica Spaulding,Roy B. Tishler,Berta Roth,Rosana del Carmen Viroglio,Varagur Venkatesan,Ilya Romanov,Sanjiv S. Agarwala,K. William Harter,Matthew Dugan,Anthony J. Cmelak,Arnold M. Markoe,Paul W. Read,Lynn Steinbrenner,A. Dimitrios Colevas,Charles M. Norris,Robert I. Haddad +28 more
TL;DR: Patients with squamous-cell carcinoma of the head and neck who received docetaxel plus cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy had a significantly longer survival than did patients who received cisPlatin and fluoride induction chemotherapyplus cheMoradiotherapy.
Journal ArticleDOI
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
Ezra E.W. Cohen,Lee S. Rosen,Everett E. Vokes,Merrill S. Kies,Arlene A. Forastiere,Francis P. Worden,Madeleine A. Kane,Eric J. Sherman,Sinil Kim,Paul Bycott,Michael A. Tortorici,David R. Shalinsky,K. F. Liau,Roger B. Cohen +13 more
TL;DR: Axitinib is a selective inhibitor of VEGFR with compelling antitumor activity in all histologic subtypes of advanced thyroid cancer.
Journal ArticleDOI
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
Alex A. Adjei,Roger B. Cohen,Wilbur A. Franklin,Clive Morris,David S. Wilson,Julian R. Molina,Lorelei J. Hanson,Lia Gore,Laura Q M Chow,Stephen Leong,Lara Maloney,Gilad Gordon,Heidi Simmons,Allison L. Marlow,Kevin Litwiler,Suzy Brown,Gregory Poch,Katie Kane,Jerry Haney,S. Gail Eckhardt +19 more
TL;DR: AZD6244 was well tolerated with target inhibition demonstrated at the recommended phase II dose and PK analyses supported twice-daily dosing, and prolonged SD was seen in a variety of advanced cancers.